(P043) Central Neurocytoma: Impact of Resection Extent and Adjuvant Radiotherapy on Survival Outcomes 

Publication
Article
OncologyOncology Vol 29 No 4_Suppl_1
Volume 29
Issue 4_Suppl_1

Adjuvant RT was delivered to a minority of CNC patients after either GTR or STR in this national database, though patients were more likely to receive RT after STR. Long-term OS was excellent for all subgroups, and there was no clear evidence of resection extent or adjuvant RT influencing survival outcomes. Since our database is subject to selection bias and limited by a lack of information regarding local recurrence, salvage therapies, exact extent of STR, and RT technique, further research is needed to validate our findings.

Yi An, MD, Yu B. James, MD, Jiang Wen, MD, PhD, Henry S. Park, MD, MPH; Yale University School of Medicine; UT MD Anderson Cancer Center

INTRODUCTION: Central neurocytoma (CNC) is an uncommon benign/borderline malignant tumor of the central nervous system that often causes symptoms due to extension into the ventricular system. Maximal surgical resection is the standard of care, but indications for adjuvant radiotherapy (RT) are unclear. Our goal was to analyze the impact of resection extent and adjuvant radiotherapy on survival outcomes using a population-based CNC dataset.

METHODS: We identified all patients in the Surveillance, Epidemiology, and End Results (SEER) database diagnosed with CNC (ICD-O-3 histology code 9506-1) in 2004–2011. Only those who received gross total resection (GTR) and subtotal resection (STR) were included. Chi-square analysis assessed the associations between demographic/clinical characteristics and the utilization of GTR and RT. Overall survival (OS) outcomes were analyzed using Kaplan-Meier analysis and the log-rank test.

RESULTS: We included 203 patients, with a median age of 31 years; 46% of patients were male, and 80% of patients were white. GTR was performed in 47% of patients, with the remainder receiving STR. Adjuvant RT was delivered to 15% of patients, including 9% after GTR and 20% after STR (P = .018). Age, sex, race, diagnosis year, World Health Organization (WHO) grade, and tumor size were not significantly associated with GTR or RT utilization. OS was 87% at 5 years for all patients, with a median follow-up of 39 months. There was no significant OS benefit with GTR compared with STR (89% vs 86%; P = .82). There was also no significant OS benefit with RT after either GTR (86% with RT vs 90% without RT at 5 years; P = .76) or STR (79% with RT vs 89% without RT at 5 years; P = .53).

CONCLUSION: Adjuvant RT was delivered to a minority of CNC patients after either GTR or STR in this national database, though patients were more likely to receive RT after STR. Long-term OS was excellent for all subgroups, and there was no clear evidence of resection extent or adjuvant RT influencing survival outcomes. Since our database is subject to selection bias and limited by a lack of information regarding local recurrence, salvage therapies, exact extent of STR, and RT technique, further research is needed to validate our findings.

Proceedings of the 97th Annual Meeting of the American Radium Society - americanradiumsociety.org

Articles in this issue

(P005) Ultrasensitive PSA Identifies Patients With Organ-Confined Prostate Cancer Requiring Postop Radiotherapy
(P001) Disparities in the Local Management of Breast Cancer in the United States According to Health Insurance Status
(P002) Predictors of CNS Disease in Metastatic Melanoma: Desmoplastic Subtype Associated With Higher Risk
(P003) Identification of Somatic Mutations Using Fine Needle Aspiration: Correlation With Clinical Outcomes in Patients With Locally Advanced Pancreatic Cancer
(P004) A Retrospective Study to Assess Disparities in the Utilization of Intensity-Modulated Radiotherapy (IMRT) and Proton Therapy (PT) in the Treatment of Prostate Cancer (PCa)
(S001) Tumor Control and Toxicity Outcomes for Head and Neck Cancer Patients Re-Treated With Intensity-Modulated Radiation Therapy (IMRT)-A Fifteen-Year Experience
(S003) Weekly IGRT Volumetric Response Analysis as a Predictive Tool for Locoregional Control in Head and Neck Cancer Radiotherapy 
(S004) Combination of Radiotherapy and Cetuximab for Aggressive, High-Risk Cutaneous Squamous Cell Cancer of the Head and Neck: A Propensity Score Analysis
(S005) Radiotherapy for Carcinoma of the Hypopharynx Over Five Decades: Experience at a Single Institution
(S002) Prognostic Value of Intraradiation Treatment FDG-PET Parameters in Locally Advanced Oropharyngeal Cancer
(P006) The Role of Sequential Imaging in Cervical Cancer Management
(P008) Pretreatment FDG Uptake of Nontarget Lung Tissue Correlates With Symptomatic Pneumonitis Following Stereotactic Ablative Radiotherapy (SABR)
(P009) Monte Carlo Dosimetry Evaluation of Lung Stereotactic Body Radiosurgery
(P010) Stereotactic Body Radiotherapy for Treatment of Adrenal Gland Metastasis: Toxicity, Outcomes, and Patterns of Failure
(P011) Stereotactic Radiosurgery and BRAF Inhibitor Therapy for Melanoma Brain Metastases Is Associated With Increased Risk for Radiation Necrosis
Related Videos
Considering cystectomy in patients with bladder cancer may help with managing the shortage of Bacillus Calmette-Guerin, according to Joshua J. Meeks, MD, PhD, BS.
Anemia in patients who receive talazoparib plus enzalutamide for metastatic castration-resistant prostate cancer appears to be manageable without any compromises in patient-reported outcomes and quality of life.
Patients with locally advanced or metastatic urothelial cancer and visceral disease may particularly benefit from enfortumab vedotin plus pembrolizumab, according to Amanda Nizam, MD.
High-grade adverse effects with zanidatamab plus palbociclib and fulvestrant seem to be uncommon in patients with HER2-positive, hormone receptor–positive, metastatic breast cancer, according to Sara Hurvitz, MD, FACP.
Black male patients with breast cancer appear to experience worse survival outcomes compared with White patients when controlling for clinicopathological variables, according to Jason (Jincong) Q. Freeman, MPH, MS.
Results from the ECOG-ACRIN E4112 trial appear to support the use of DCIS scores for identifying patients with breast cancer who may be eligible to omit radiotherapy following MRI-guided surgery.
Providers should inform patients with breast cancer that selecting later-line therapies following prior treatment with CDK4/6 inhibitors is a “developing area,” says Abigail M. Johnston, JD.
Data from the phase 3 NATALEE trial highlight a positive toxicity profile for ribociclib as an adjuvant therapy for patients with hormone receptor–positive, HER2-negative breast cancer, says Neil M. Iyengar, MD.
Future research will focus on ctDNA dynamics change over time in the full translational cohort of patients with hormone receptor–positive breast cancer in the phase 3 monarchE study, says Stephanie L. Graff, MD.
Findings from a National Cancer Database analysis highlight no statistically significant differences in survival outcomes with chemotherapy for patients over 81 years old with triple-negative breast cancer compared with those who do not receive chemotherapy.
Related Content